Skip to content

Biote Corp. BTMD Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

NAG
Niagen Bioscience, Inc. Common StockNAGE

Other financials

Income statement

See full
Revenue$44.9M-8.3%
Gross profit$31.0M-14.9%
Operating income$3.2M-67.3%
Net income$2.3M-83.4%
EPS (diluted)$0.06-83.8%

Balance sheet

See full
Cash & equivalents$5.3M-87.2%
Total debt$103.4M-5.5%
Total equity-$56.1M+37.7%
Total assets$89.0M-27.8%

Cash flow

See full
Operating cash flow$3.9M-39.7%
CapEx$362.0K-77.8%
Free cash flow$3.5M-26.8%

Valuation

See full
Market cap$57.33M-51.2%
Enterprise value$155.43M-26.5%
P/E3.7×-0.1×
P/S0.3×-0.3×

Profitability

See full
Gross margin70.1%-1.2pp
Operating margin15.4%-0.1pp
Net margin8.3%-2.3pp
FCF margin15.3%-3.2pp

Returns & leverage

See full
Return on equity-21.4%
Debt / equity9.1×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Biote Corp. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Biote Corp.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biote Corp.'s accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biote Corp.'s accrued progress collections and price adjustments?
Biote Corp. (BTMD) reported accrued progress collections and price adjustments of $922K in Q1 2026.
How has Biote Corp.'s accrued progress collections and price adjustments changed year-over-year?
Biote Corp.'s accrued progress collections and price adjustments decreased by 36.4% year-over-year, from $1.45M to $922K.
What is the long-term trend for Biote Corp.'s accrued progress collections and price adjustments?
Over 4 years (2021 to 2025), Biote Corp.'s accrued progress collections and price adjustments has grown at a 8.1% compound annual growth rate (CAGR), from $802K to $1.1M.